

Bio-identical Hormone Replacement Reference list (updated 2024)

Carson PR, Eklind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulating androgens. *Obstet Gynecol.* 1997 Dec;90(6):995-8.

Basbug M, Aygen E, Taysir M, et al. Twenty two weeks of transdermal estradiol increases sex hormonebinding globulin in surgical menopausal women. *Eur J Obstet Gynecol Reprod Biol.* 1997 Jun;73(2):149-52.

Slater CC, Zhang C, Hodis HN, et al. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. *J Reprod Med.* 2001 Dec;46(12):1052-6.

Snabes MC, Payne JP, Kopeckel HA, et al. Physiologic estradiol replacement therapy and cardiac structure and function in normal postmenopausal women: a randomized, double-blind, placebo-controlled, crossover trial. *Obstet Gynecol.* 1997 Mar;89(3):332-9.

Chen FP, Lee N, Soong YK, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on cardiovascular risk factors. *Menopause.* 2001 Sept-Oct;8(5):347-52.

Karjalainen A, Heikkinen J, Savolainen M, et al. Metabolic changes induced by peroral oestrogen and transdermal oestrogen gel therapy. *Br J Obstet Gynaecol.* 1997 Nov;104 Suppl 16:38-43.

Walsh BW, Uih H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. *J Lipid Res.* 1994 Nov;35(11):2083-93.

Haines C, Chung T, Chang A, et al. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study. *Arch Intern Med.* 1996 Apr 22;156(8):866-72.

Hea KA. Estriol: safety and efficacy. *Altern Med Rev.* 1998 Apr;3(2):101-13.

Tangosinis VA, Alosa MF, Greenblatt RB. Estriol in the management of the menopause. *JAMA.* 1978 Apr 21;239(16):1638-41.

Yang TS, Tsan SH, Chang SP, et al. Efficacy and safety of estriol replacement therapy for climacteric women. *Zhonghua Yi Xue Zhi (Taipei).* 1995 May;55(5):386-91.

Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of natural and surgically induced menopause. *Hum Reprod.* 2000 May;15(5):1028-36.

Nozaki M, Hashimoto K, Inoue Y, et al. Usefulness of estriol for the treatment of bone loss in postmenopausal women. *Nippon Sanka Fujink Gakkai Zasshi.* 1996 Feb;48(2):83-8.

Minaguchi H, Uemura T, Shirasu K, et al. Effect of estriol on bone loss in postmenopausal Japanese women: a multicenter prospective open study. *J Obstet Gynaecol Res.* 1996 Jun;23(2):259-65.

Nishibe A, Morimoto S, Hirata K, et al. Effect of estradiol and bone mineral density of lumbar vertebrae in elderly and postmenopausal women. *Nippon Ronen Igakkai Zasshi.* 1996 May;33(5):353-9.

Hayashi T, Ito I, Kano H, et al. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. *J Gerontol A Biol Sci Med Sci.* 2000 Apr;55(4):B183-90.

Itoi H, Minakami H, Sato I. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. *Maturitas.* 1997 Sep;28(1):11-7.

Itoi H, Minakami H, Iwasaki R, et al. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. *Maturitas.* 2000 Oct 31;36(3):217-22.

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med.* 1993 Sep;329(11):753-6.

de Lignieres B. Oral micronized progesterone. *Clin Ther.* 1999 Jan;21(1):41-60.

Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. *Fertil Steril.* 1985 Nov;44(5):626.

Norman TR, Morse CA, Dennerstein L. Comparative bioavailability of orally and vaginally administered progesterone. *Fertil Steril.* 1991 Dec;56(6):1034-9.

Tavaniotou A, Smith J, Bourgain C, et al. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. *Hum Reprod Update.* 2000 Mar-Apr;6(2):139-48.

Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol.* 1999 Aug;94(2):225-8.

Bolaji II, Grimes H, Mortimer C, et al. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects of plasma lipids, lipoproteins and liver function parameters. *Eur J Obstet Gynecol Reprod Biol.* 1993 Jan;48(1):61-8.

Dari E, Axelsson O. Carotid intima-media thickness during treatment with estradiol and natural progesterone. *Gynecol Endocrinol.* 1999 Jun;7(2):111-4.

Arafat ES, Hargrove JT, Maxson WS, et al. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. *Am J Obstet Gynecol.* 1988 Nov;159(5):1203-9.

Glaser RL, Zava DT, Wurtzbacher D. Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. *Gynecol Obstet Invest.* 2008;66(2):111-8.

Miller KK. Androgen deficiency in women. *J Clin Endocrinol Metab.* 2001 Jun;86(6):2395-401.

Miller K, Corcoran C, Armstrong C, et al. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. *J Clin Endocrinol Metab.* 1998 Aug;83(8):2717-25.

Davis SR, Walker KB. Sex testosterone and body composition and relationships with lipids in postmenopausal women. *Menopause.* 2000 Nov-Dec;7(6):395-401.

Labrie F, Diamond P, Cusan L, et al. Effect of 12 month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab.* 1997 Oct;82(10):3498-505.

Legrain S, Massien C, Lahou N, et al. Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. *J Clin Endocrinol Metab.* 2000 Sep;85(9):3208-17.

Barnhart KT, Freeman E, Grisso JA, et al. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. *J Clin Endocrinol Metab.* 1999 Nov;84(11):3896-902.

Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clin Endocrinol (Oxf).* 1998 Oct;49(4):421-32.

Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. *Obstet Gynecol.* 1989 Apr;73(4):606-12.

Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med.* 2000 Sep 7;343(10):602-8.

Nahoul K, Behennin L, Jondet M, et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. *Maturitas.* 1993 May;16(3):185-202.

Lee JR. *What Your Doctor May Not Tell You About Menopause.* New York, NY: Warner Books; 1996:267.

Gilston G, Marsden T. *You've Hit Menopause: Now What? 3 Simple Steps to Restoring Hormone Balance.* Calgary, Alberta, Canada: Blitzprint;2003:110-3.

Herrington T. *The Hormone Handbook.* Surrey, United Kingdom: International Medical Publications; 2006:134, 175-6, 204.

Stephenson K, Awakening Atkins, Tyler, TX: Health, Heart & Mind Institute; 2004:239, 242, 249, 268, 299, 306, 335.

Taylor EB, Bell-Taylor A. *Are Your Hormones Making You Sick.* United States of America: Physicians Natural Medicine Inc.;2000:174, 182.

Norstrup C. *The Wisdom of Menopause.* New York, NY: Bantam Book; 2001:127, 162.

Dessole S, Rubattu G, Ambrosini G, et al. Efficacy of low-dose intravaginal estradiol on urogenital aging in postmenopausal women. *Menopause.* 2004 Jan-Feb;11(1):49-56.

Chury AC, Speck NM, deMoura KF, Belfort PN, Sakano C, Ribatta JC. Efficacy of vaginal use of topical estradiol in postmenopausal women with urogenital atrophy. *Clin Exp Obstet Gynecol.* 2011;38(2):143-145.

Grisser H, Skonietzke S, Fischer T, Fiedler K, Susskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. *Maturitas.* 2012 Apr;71(4):360-368. [Epub 2012 Jan 18.](#)

Palacios S, Castelo-Branco C, Cancele MJ, et al. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. *Maturitas.* 2005;50:98-104.

Biglia N, Peano E, Sgandura P, et al. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: A preliminary study. *Gynecol Endocrinol.* 2010 Jun;26(6):404-412.

Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. *Menopause.* 2012 Oct; 19(10):1130-1139.

Chollet JA, Carter C, Meyn LA, Mermelstein F, Bak JI. Efficacy and safety of vaginal estriol and progesterone in postmenopausal women with atrophic vaginitis. *Menopause.* 2009 Sep-Oct;16(5):978-983.

Shifren JL, Davis S, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NMI study. *Menopause.* 2006 Sep-Oct;13(5):770-779.

Braunstein GD. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. *J Sex Med.* 2007;4:859-866.

Goldstar R, Griganti E, Tran J, Wolfe R, Davis S. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *Menopause.* 2003 Sep-Oct;10(5):390-398.

White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. *Am Heart.* 2012;163:27-32.

Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. *J Natl Cancer Inst.* 2007 May 2;99(9):672-679.

Witherby S, Johnson J, Hargrove JT, et al. Testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. *Oncologist.* 2011;16(4):424-431. [Epub 2011 Mar 8.](#)

Labrie F, Archer D, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. *Menopause.* 2009 Sep-Oct;16(5):923-931.

Labrie F, Archer D, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. *Menopause.* 2009 Sep-Oct;16(5):897-906.

Labrie F, Belander A, et al. Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. *J Steroid Biochem Mol Biol.* 2007;107:57-69.

Van Rooij K, Bloemers J, de Leeuw L, et al. Pharmacokinetics of three doses of sublingual testosterone in healthy premenopausal women. *Psychoneuroendocrinology.* 2012;37:773-781.

Singh AB, Lee ML, Sinha-Hikim I, et al. Pharmacokinetics of a testosterone gel in healthy postmenopausal women. *J Clin Endocrinol Metab.* 2006;91(1):136-144.

Fooldi E, Reuter SE, Bell RJ, Robinson PJ, Davis SR. Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. *Menopause.* 2014 Mar;22(1):1-6.

Reed-Kane D, Coffey JJ, Foy E, MacCara ME. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. *International Journal of Pharmacological Compounding.* 2004;8:167.

Hernández Valencia M, Angeles L, Saucedo R, Basurto L, Zárate A. Therapy with dehidroepiandrosterone improves symptoms in perimenopausal women. *Ginecología y obstetricia de México.* 2005;73:245.

Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low Dose of Transdermal Estradiol Gel for Treatment of Symptomatic Postmenopausal Women: A Randomized Controlled Trial. *Obstetrics & Gynecology.* 2007;109:588-596.

Grady D, Vittinghoff E, Lin F, et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. *Menopause.* 2007;14:391-396.

Waestgen LE, Brown JS, Vittinghoff E, et al. The effect of ultra-low-dose transdermal estradiol on urinary incontinence in postmenopausal women. *Obstet Gynecol.* 2005;106:946-952.

Huang A. The effect of ultra-low-dose transdermal estradiol on sexual function in postmenopausal women. *Obstet Gynecol.* 2008;198:265.e1-265.e7.

Bachmann GA, Schaefer S, Utian WH. Lowest Effective Transdermal 17β-Estradiol Dose for Relief of Hot Flashes in Postmenopausal Women: A Randomized Controlled Trial. *Obstetrics & Gynecology.* 2007;110:771-779.

Buster JE. Low-dose estradiol spray: a novel treatment for vasomotor instability in postmenopausal women. *Women's health (London, England).* 2009;5:23-28.

Matsu S, Yasui T, Tani A, et al. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women. *Climacteric: the journal of the International Menopause Society.* 2014;17:191.

Terauchi M, Honjo H, Mizunuma H, Aso T. Effects of oral estradiol and levonorgestrel on cardiovascular risk markers in postmenopausal women. *Arch Gynecol Obstet.* 2012;285:1647-1656.

Shehnan-Breen C, Anderson G, Gibson D, Kausz AT, Ott S. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. *Kidney Int.* 2003;64:290-294.

Mattsson LA, Christiansen C, Colau JC, et al. Clinical efficacy of intranasal and oral 17beta-estradiol for postmenopausal symptoms. *Obstet Gynecol.* 2000;182:545.

Andréen L, Sundström-Poromaa I, Bixo M, et al. Allogestronolone concentration and mood—a bimodal association in postmenopausal women treated with oral progesterone. *Psychopharmacology (Berl)* . 2006;187:209221. 77.) Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K. Efficacy and safety of oral estriol for managing postmenopausal symptoms. *Maturitas.* 2000;34:169-177.

Gränberg S, Eurenius K, Lindgren R, et al. The effects of oral estriol on the endometrium in postmenopausal women. *Maturitas.* 2002;42:149-156.

Jaisamran U, Tiratatanachai S, Chakittipaisa S, Grob P, Prasasvay V, Tachekraichana N. Ultra-low-dose estradiol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. *Climacteric.* 2013;16:347-355.

Buhling KJ, Eydelder U, Borregaard S, Schlegelmich R, Susskind M. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. *Arzneimittelforschung.* 2012;62:378.

Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. *Arch Gynecol Obstet.* 2012;285:397-403.

15. Du JY, Sanchez P, Kim J, Azen CG, Zava DT, Stanczyk FZ. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. *Menopause.* 2013;20:1169-1175.

Stephenson K, Neuenschwander PF, Kurdowska AK, Pinson B, Price C. Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women. *International Journal of Pharmaceutical Compounding.* 2008;12:295.

Wren BG, McFarland K, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. *Climacteric: the journal of the International Menopause Society.* 2000;3:155.

Birzniece V, Umpelby MA, Poljak A, Handelsman DJ, Ho KK. Oral low-dose testosterone administration induces whole-body protein anabolism in postmenopausal women: a novel liver-targeted therapy. *Eur J Endocrinol.* 2013;169:321.

Davis SR, Moreau M, Hargrove JT, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. *N Engl J Med.* 2008;359:2005-2017.

Study identifies effective testosterone dose for women. *Havd Womens Health Watch.* 2014;22:8.

Davis SR, Jane F, Robinson PJ, et al. Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy. *Clin Endocrinol (Oxf).* 2014;81:621-628.

Davison S, Thipphawong J, Blanchard J, et al. Pharmacokinetics and Acute Safety of Inhaled Testosterone in Postmenopausal Women. *The Journal of Clinical Pharmacology.* 2005;45:177-184.

Panjarji M, Bell RJ, Jane F, Adams J, Morrow C, Davis SR. The safety of 52 weeks of oral DHEA therapy for postmenopausal women. *Maturitas.* 2009;63:240-245.

Hirshman S, Wells E, Wierman ME, et al. The effect of dehydroepiandrosterone (DHEA) on recognition memory decision processes and discrimination in postmenopausal women. *Psychon Bull Rev.* 2003;10:125-134.

Getzmann AR, Puchner S, Bredemeyer S, Grob P, Prasasvay V, Tachekraichana N. Ultra-low-dose estradiol and lactobacilli in the response to adrenocorticotrophic hormone in early and late postmenopausal women. *Gynecological Endocrinology.* 2006;22:627-635. 93.) Hackbert L, Heiman JR. Acute dehydroepiandrosterone (DHEA) effects on sexual arousal in postmenopausal women. *J Womens Health Gen Based.* 2002;11:155-162.

Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. *Climacteric.* 2011;14:661-668.

Labrie F, Labrie C, Cusan L, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. *J Steroid Biochem Mol Biol.* 2008;111:178-194.

Research: Research Conducted at Mayo Clinic Has Provided New Information about Clinical Trials and Studies. *Health & Medicine Week [serial online].* 2013;13:18.

Levy T, Gutwirth S, Bar-Hava I, et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. *Hum Reprod.* 1999;14:606-610.

Lipsett MB. Steroid hormones. *Reproductive Endocrinology* 1978:84.

Du JY, Sanchez P, Kim J, Azen CG, Zava DT, Stanczyk FZ. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. *Menopause.* 2013 Nov;20(11):1169-75.

Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. *Int J Pharm Compd.* 2013 Jan-Feb;17(1):74-85.